Enzyme Replacement Therapy in an Infant with Pompe's Disease with Severe Cardiomyopathy

Tanzer F., Buyukkayhan D., Mutlu E. C. , Korkmaz F. K.

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, vol.22, no.12, pp.1159-1162, 2009 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 12
  • Publication Date: 2009
  • Doi Number: 10.1515/jpem.2009.22.12.1159
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.1159-1162


Pompe's disease is a glycogen storage disease (type II) characterized by inherited autosomal recessive transmission. A 4 month-old girl presented with rapid disease progression, exhibiting severe hypotonia, and hypertrophic cardiomyopathy, progressing to respiratory failure by the age of 9 months. Despite its low incidence, infantile Pompe's disease is lethal. The availability of an effective treatment has created an urgent need to improve knowledge and early diagnosis of this disease. The clinical response is variable from patient to patient with a better effect in patients enrolled earlier. The only clinically available therapy for Pompe's disease is enzyme replacement therapy (ERT). Gene therapy is still not available for Pompe's disease due to lack of suitable vectors for long-term and tissue-specific expression. Recombinant human alpha-glucosidase remains a hope for patients.